Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Current Opinion in Biotechnology|December 28, 2020
Delivery of CRISPR-Cas systems using phage-based vectorsClément Fage, Nicolas Lemire, Sylvain MoineauViruses|February 26, 2022
Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial CellsClément Fage, Mathilde Hénaut, Julie Carbonneau, et al.Journal of Medical Virology|August 10, 2017
The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virusClément Fage, Andrés Pizzorno, Chantal Rhéaume, et al.Antiviral Therapy|October 31, 2017
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitorsClément Fage, Véronique Tu, Julie Carbonneau, et al.Antiviral Research|April 21, 2018
Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 virusesVéronique Tu, Yacine Abed, Clément Fage, et al.Antiviral Research|April 29, 2020
Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in miceYacine Abed, Clément Fage, Liva Checkmahomed, et al.Viruses|December 26, 2018
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase InhibitorsClément Fage, Yacine Abed, Liva Checkmahomed, et al.Antiviral Research|November 14, 2016
The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitnessVéronique Tu, Yacine Abed, Xavier Barbeau, et al.Antiviral Research|July 20, 2019
The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitorsYacine Abed, Clément Fage, Liva Checkmahomed, et al.Emerging Infectious Diseases|March 19, 2019
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, CanadaYacine Abed, Clément Fage, Patrick Lagüe, et al.Pageof 2